- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Compass Pathways Plc (CMPS)
Compass Pathways Plc stock price live, this page displays NASDAQ CMPS stock exchange data. View the CMPS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Compass Pathways Plc real time stock price chart below.
What Is the Compass Pathways Plc Stock Price Today?
The Compass Pathways Plc stock price today is 4.59.
What Is the Stock Symbol for Compass Pathways Plc?
The stock symbol for Compass Pathways Plc is ""CMPS.""
What Stock Exchange Does Compass Pathways Plc Trade On?
Compass Pathways Plc is listed and trades on the NASDAQ stock exchange.
Is Compass Pathways Plc a Good Stock to Buy?
Determining whether Compass Pathways Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CMPS quote. (ISIN: US20451W1018)
What Is the Compass Pathways Plc Stock Price Today?
The Compass Pathways Plc stock price today is 4.59.
What Is the Stock Symbol for Compass Pathways Plc?
The stock symbol for Compass Pathways Plc is ""CMPS.""
What Stock Exchange Does Compass Pathways Plc Trade On?
Compass Pathways Plc is listed and trades on the NASDAQ stock exchange.
Is Compass Pathways Plc a Good Stock to Buy?
Determining whether Compass Pathways Plc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CMPS quote. (ISIN: US20451W1018)
4.59
-0.01(-0.22%)
Real-time Data·
Fair Value
An estimate of a Compass Pathways's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.50
4.67
52 wk Range
2.25
8.54
CMPS Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
CMPS is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a Compass Pathways's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
4.504.67
52 wk Range
2.258.54
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CMPS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Compass Pathways's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
16.00
Upside
+248.58%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
2 analysts have revised their earnings upwards for the upcoming period
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Compass Pathways Plc Company Profile
COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. The company was incorporated in 2020 and is headquartered in London, the United Kingdom.
Compass Pathways Plc SWOT Analysis
Psychedelic Pionee | Compass Pathways leads the charge in developing psilocybin-based therapy COMP360 for treatment-resistant depression, navigating clinical trials and regulatory hurdles |
Market Potential | Analysts project peak revenues of $2.3 billion for COMP360, with a potential market exceeding $1 billion in treatment-resistant depression alone |
Regulatory Landscape | Explore how Compass Pathways' methodical approach aligns with FDA guidance, potentially expediting approval in an evolving regulatory environment for psychedelic therapies |
Financial Outlook | With analyst price targets ranging from $12 to $60, Compass Pathways faces challenges but maintains a strong liquidity position as it advances towards commercialization |
Compass Pathways Plc Earnings Call Summary for Q4/2024
- Q4 2024 EPS met forecast at -0.63; stock rose 7.03% premarket to $3.96 despite no revenue
- Net loss of $155.1M for 2024; R&D expenses increased to $119M from $87.5M in 2023
- Cash runway extended to H2 2026 with $165.1M cash on hand and $140M from January financing
- Over 90% recruitment for COMP005 Phase III trial; top-line data expected Q2 2025
- 2025 guidance: $120M-$145M net cash used in operations; focus on TRD and PTSD opportunities
Last Updated: 27/02/2025, 15:08
Read Full TranscriptCompare CMPS to Peers and Sector
Metrics to compare | CMPS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCMPSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.2x | −2.7x | −0.5x | |
PEG Ratio | −0.14 | −0.05 | 0.00 | |
Price/Book | 2.7x | 2.3x | 2.6x | |
Price / LTM Sales | - | 10.3x | 3.3x | |
Upside (Analyst Target) | 160.9% | 197.2% | 43.5% | |
Fair Value Upside | Unlock | 14.3% | 6.3% | Unlock |
Analyst Ratings
8 Buy
1 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 16.00
(+248.58% Upside)
Earnings
Latest Release
Jul 31, 2025
EPS / Forecast
-0.41 / -0.42
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Compass Pathways Trade On?
Compass Pathways is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Compass Pathways?
The stock symbol for Compass Pathways is "CMPS."
What Is the Compass Pathways Market Cap?
As of today, Compass Pathways market cap is 444.21M.
What Is Compass Pathways's Earnings Per Share (TTM)?
The Compass Pathways EPS (TTM) is -1.73.
When Is the Next Compass Pathways Earnings Date?
Compass Pathways will release its next earnings report on 29 Oct 2025.
From a Technical Analysis Perspective, Is CMPS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Compass Pathways Stock Split?
Compass Pathways has split 0 times.
How Many Employees Does Compass Pathways Have?
Compass Pathways has 166 employees.
What is the current trading status of Compass Pathways (CMPS)?
As of 05 Aug 2025, Compass Pathways (CMPS) is trading at a price of 4.59, with a previous close of 4.60. The stock has fluctuated within a day range of 4.50 to 4.67, while its 52-week range spans from 2.25 to 8.54.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.